Genomic newborn screening: ICoNS

Gene: KCNJ11

I don't know

Reviewed at Gene List subcommittee meeting 13/3/26.

There are arguments both for and against including this gene in gNBS -- decision may depend on level of integration between clinical-laboratory pathways and turnaround time.

Created: 13 Mar 2026, 7:27 a.m. | Last Modified: 13 Mar 2026, 7:29 a.m.

Panel Version: 0.35

Mode of inheritance
BOTH monoallelic and biallelic, autosomal or pseudoautosomal

Phenotypes
Diabetes mellitus, transient neonatal, 3 610582 Diabetes, permanent neonatal, with or without neurologic features 606176 Hyperinsulinemic hypoglycemia, familial, 2 601820

Red List (low evidence)

1) Mutations in the KCNJ11 gene affect the ATP-sensitive potassium (KATP) channel in pancreatic β-cells, which links cellular metabolism to insulin secretion. When gain-of-function mutations occur, the KATP channel remains excessively open, preventing β-cell depolarization and impairing insulin release; this mechanism causes monogenic diabetes that can present either as Neonatal diabetes or as MODY13 depending largely on mutation severity and age of onset. Heterozygous activating mutations in KCNJ11 were first shown to cause neonatal diabetes, demonstrating that increased KATP channel activity suppresses insulin secretion and leads to hyperglycemia (Shimomura & Maejima 2017). The most severe activating mutations can also affect neuronal KATP channels, leading to the syndromic form known as DEND syndrome, characterized by developmental delay, epilepsy, and neonatal diabetes. Because milder activating variants may allow partial insulin secretion, diabetes can appear later in life and be classified as MODY13, placing both conditions on a clinical spectrum of KATP channel overactivity (De Franco et al. 2020). As activating mutations in KCNJ11 can lead either to neonatal diabetes or to MODY13, genotype alone does not reliably predict the age of disease onset. MODY13 typically manifests much later in life; reported cases show onset ranging from approximately 9 to 28 years of age, with many patients developing diabetes during adolescence (Chen et al. 2023). Because gNBS programs generally target disorders that produce symptoms in early childhood (e.g., before about 5 years of age) and require early intervention, MODY13 falls outside the scope of these screening criteria. Consequently, detecting a KCNJ11 activating mutation in a newborn would not allow clinicians to determine whether the child will develop neonatal diabetes in infancy or a later-onset MODY13 phenotype. For this reason, neonatal diabetes cannot reliably be included as a standalone condition in gNBS based solely on KCNJ11 variants.

In contrast, the opposite mechanism, loss-of-function mutations in KATP channel genes such as KCNJ11, causes Congenital hyperinsulinism (familial hyperinsulinemic hypoglycemia), where defective channels cannot open, leading to persistent β-cell depolarization and inappropriate insulin secretion even during hypoglycemia. Most severe KATP-related CHI cases follow an autosomal recessive inheritance pattern, although some mutations can act dominantly and produce milder phenotypes (Kapoor et al. 2011). When focusing specifically on autosomal recessive KCNJ11-related CHI, biallelic inactivating mutations disrupt KATP channel activity and typically result in severe neonatal hypoglycemia. From a screening perspective, CHI typically presents with symptomatic hypoglycemia very shortly after birth, meaning it is usually detected rapidly through clinical glucose monitoring, thereby limiting the added value of gNBS (Stanley, 2016).

In their comparative analysis of genomic newborn sequencing initiatives, Thomas Minten and colleagues reported that the KCNJ11 gene is included in 17 of the 27 gNBS programs evaluated in the study. These programs include BabySeq, BabyDetect, BeginNGS, Early Check, the GUARDIAN study, NESTS (Newborn Sequencing in Genomic Medicine and Public Health), gnSTAR, the Chen et al. newborn sequencing cohort, the Wang et al. newborn sequencing study, the Yang et al. multicenter sequencing study, the PerkinElmer genomic newborn screening panel, the PerkinElmer GS program, the NeoExome panel, BabyScreen+, NeoSeq, the targeted panel described by Huang et al. (inborn disorders of neonates), and the sequencing pilot described by Jian et al. (WGS screening pilot). However, the analysis compares gene inclusion rather than specific target conditions, and it is therefore not always clear which disease associated with KCNJ11 (e.g., monogenic diabetes or congenital hyperinsulinism) is intended to be screened for in each program.

2) ClinGen curation
The KCNJ11 gene has been curated by Clinical Genome Resource (ClinGen) for its role in monogenic diabetes. ClinGen has classified the association between KCNJ11 and KATP-channel–related diabetes as Definitive, based on strong genetic and experimental evidence. Pathogenic variants in KCNJ11 are well established causes of Neonatal diabetes and MODY13 through gain-of-function effects on the KATP channel. The gene is also associated with Congenital hyperinsulinism through loss-of-function variants. ClinGen curation therefore supports a strong gene–disease relationship for both monogenic diabetes and hyperinsulinism.

3) Treatability and evidence
Clinical studies have demonstrated that a large proportion of individuals with KCNJ11-related neonatal diabetes can successfully switch from insulin injections to sulfonylureas, leading to improved glycemic control and quality of life (Pearson et al., 2006, New England Journal of Medicine). In addition to improving metabolic control, early treatment may also improve neurological outcomes in some patients with syndromic forms of the disease such as DEND syndrome.
For CHI (caused by loss-of-function KATP mutations), treatment may include diazoxide therapy, which acts as a KATP channel opener, although many recessive KATP-channel cases are diazoxide-unresponsive and may require pancreatectomy. Early diagnosis is therefore clinically important to prevent severe hypoglycemia and neurological damage.

4) Impact of treatment
The clinical impact of appropriate treatment can be substantial:
KCNJ11 neonatal diabetes --> switch from insulin to oral sulfonylureas, improved glycemic control, reduced treatment burden, potential improvement in neurological symptoms when therapy is initiated early
Congenital hyperinsulinism --> diazoxide or octreotide therapy may prevent hypoglycemia,
early recognition prevents hypoglycemic brain injury

5) Issues with genomic screening
Despite the strong gene–disease association and available treatments, several challenges exist for genomic newborn screening of KCNJ11.
Phenotypic ambiguity --> same mutation type in KCNJ11 can cause neonatal diabetes or MODY13 which have different ages of onset

Technical sequencing considerations --> from a sequencing perspective, KCNJ11 is technically straightforward to analyze: small gene, no pseudogenes, good coverage in both exome and genome sequencing

Clinical detection without genomics --> for autosomal recessive KCNJ11-related congenital hyperinsulinism, symptoms usually appear shortly after birth with severe hypoglycemia. Because neonatal glucose levels are routinely monitored, many cases are detected rapidly through standard clinical care, limiting the additional value of genomic newborn screening. Neonatal diabetes presents with persistent hyperglycemia in infancy, often leading to rapid clinical investigation.
Sources: Other

Created: 12 Mar 2026, 9:58 p.m.

Mode of inheritance
BOTH monoallelic and biallelic, autosomal or pseudoautosomal

Phenotypes
Familial Hyperinsulinemic hypoglycemia 2 (CHI); MODY type 13; neonatale diabetes; DEND Syndrome

Publications

• PMID: 28824061
• PMID: 32027066
• PMID: 21674179
• PMID: 38226203
• PMID: 26908106